Gastric Cancer
Conditions
Interventions
UFT:300-600 mg/body/day Day 1-5 One course takes 7 days. In total of one year administration of UFT and TS-1
Sponsors
Division of Gastrointestinal Surgery, Kobe University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Histological proven gastric carcinoma D>=2 lymph node dissection and curability A or B stage II/III(except for T1) Age 20-80 years Despite adjust dose and regimen, duration of TS-1 is less than 6 months caused by adverse effects. within 1-7 weeks after dropping TS-1 Adequate cardiac, hepatic, renal, respiratory, and bone marrow functions. Written informed consent.
Exclusion criteria
Exclusion criteria: administration contraindication of UFT Severe complications, such as paralytic ileus, bowel obstruction, interstitial pneumonitis, pulmonary fibrosis, regular use of insulin or uncontrollable diabetes mellitus, arrhythmias, heart failure, liver cirrhosis, and active hepatitis) Severe watery diarrhea. HIV+ Exclude the patients who are recognized as inadequate patients by doctors with responsibility in this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Feasibility | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety of UFT Relapse-Free Survival Overall Survival | — |
Countries
Japan
Contacts
Public ContactTakashi Kamigaki
Kobe University Graduate School of Medicine Division of Gastrointestinal Surgery
Outcome results
None listed